应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
PLX Protalix BioTherapeutics Inc
已收盘 02-04 16:00:00 EST
2.90
+0.17
+6.23%
盘后
2.88
-0.02
-0.69%
19:47 EST
最高
2.97
最低
2.74
成交量
258.12万
今开
2.74
昨收
2.73
日振幅
8.42%
总市值
2.33亿
流通市值
1.76亿
总股本
8,042万
成交额
739.94万
换手率
4.25%
流通股本
6,076万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Protalix Biotherapeutics, Inc. (De)盘中异动 早盘股价大涨5.00%报2.73美元
市场透视 · 02-03 23:00
Protalix Biotherapeutics, Inc. (De)盘中异动 早盘股价大涨5.00%报2.73美元
Protalix BioTherapeutics 第三季度每股收益为0.03美元
投资观察 · 2025-11-20
Protalix BioTherapeutics 第三季度每股收益为0.03美元
奇耶斯全球罕见疾病请求欧洲药品管理局对Elfabrio 2 mg/kg每四周给药方案的负面意见进行重新审查
投资观察 · 2025-11-20
奇耶斯全球罕见疾病请求欧洲药品管理局对Elfabrio 2 mg/kg每四周给药方案的负面意见进行重新审查
Protalix BioTherapeutics 第三季度每股收益为0.03美元
投资观察 · 2025-11-13
Protalix BioTherapeutics 第三季度每股收益为0.03美元
奇耶西全球罕见病公司申请重新审查欧洲药品管理局CHMP对Elfabrio 2 mg/kg每4周给药方案的负面意见
投资观察 · 2025-11-04
奇耶西全球罕见病公司申请重新审查欧洲药品管理局CHMP对Elfabrio 2 mg/kg每4周给药方案的负面意见
Protalix Biotherapeutics, Inc. (De)盘中异动 下午盘股价大涨5.35%
市场透视 · 2025-10-07
Protalix Biotherapeutics, Inc. (De)盘中异动 下午盘股价大涨5.35%
Protalix Biotherapeutics, Inc. (De)盘中异动 临近收盘急速拉升5.10%
市场透视 · 2025-09-25
Protalix Biotherapeutics, Inc. (De)盘中异动 临近收盘急速拉升5.10%
Protalix Biotherapeutics, Inc. (De)盘中异动 快速拉升5.06%报1.66美元
市场透视 · 2025-09-10
Protalix Biotherapeutics, Inc. (De)盘中异动 快速拉升5.06%报1.66美元
Protalix Biotherapeutics, Inc. (De)盘中异动 急速拉升5.19%报1.62美元
市场透视 · 2025-08-12
Protalix Biotherapeutics, Inc. (De)盘中异动 急速拉升5.19%报1.62美元
Protalix Biotherapeutics, Inc. (De)盘中异动 早盘大幅下跌5.15%报2.21美元
市场透视 · 2025-02-28
Protalix Biotherapeutics, Inc. (De)盘中异动 早盘大幅下跌5.15%报2.21美元
Protalix Biotherapeutics, Inc. (De)盘中异动 早盘股价大跌5.02%报2.56美元
市场透视 · 2025-02-18
Protalix Biotherapeutics, Inc. (De)盘中异动 早盘股价大跌5.02%报2.56美元
Protalix Biotherapeutics, Inc. (De)盘中异动 快速拉升5.16%
市场透视 · 2025-02-06
Protalix Biotherapeutics, Inc. (De)盘中异动 快速拉升5.16%
Protalix Biotherapeutics, Inc. (De)盘中异动 急速上涨5.38%报2.35美元
市场透视 · 2025-01-29
Protalix Biotherapeutics, Inc. (De)盘中异动 急速上涨5.38%报2.35美元
Protalix Biotherapeutics, Inc. (De)盘中异动 急速下跌5.28%报2.33美元
市场透视 · 2025-01-28
Protalix Biotherapeutics, Inc. (De)盘中异动 急速下跌5.28%报2.33美元
Protalix Biotherapeutics, Inc. (De)盘中异动 临近收盘股价大涨5.06%
市场透视 · 2025-01-24
Protalix Biotherapeutics, Inc. (De)盘中异动 临近收盘股价大涨5.06%
Protalix Biotherapeutics, Inc. (De)盘中异动 股价大涨5.41%
市场透视 · 2025-01-22
Protalix Biotherapeutics, Inc. (De)盘中异动 股价大涨5.41%
Protalix Biotherapeutics, Inc. (De)盘中异动 早盘急速下挫5.29%
市场透视 · 2025-01-14
Protalix Biotherapeutics, Inc. (De)盘中异动 早盘急速下挫5.29%
Protalix Biotherapeutics, Inc. (De)盘中异动 早盘股价大涨5.18%报2.23美元
市场透视 · 2025-01-06
Protalix Biotherapeutics, Inc. (De)盘中异动 早盘股价大涨5.18%报2.23美元
Protalix Biotherapeutics, Inc. (De)盘中异动 股价大涨5.26%
市场透视 · 2025-01-03
Protalix Biotherapeutics, Inc. (De)盘中异动 股价大涨5.26%
Protalix Biotherapeutics, Inc. (De)盘中异动 早盘股价大涨5.03%
市场透视 · 2024-12-30
Protalix Biotherapeutics, Inc. (De)盘中异动 早盘股价大涨5.03%
加载更多
公司概况
公司名称:
Protalix BioTherapeutics Inc
所属市场:
AMEX
上市日期:
--
主营业务:
Protalix Biotherapeutics, Inc.最初于1992年4月在佛罗里达州注册成立,并于2016年3月在特拉华州重新注册成立。该公司是一家生物制药公司,专注于开发、生产和商业化由专有的ProCellEx植物细胞蛋白表达系统生产的重组治疗蛋白。该公司是第一家也是唯一一家获得FDA批准的通过植物细胞表达悬浮蛋白生产的公司。该公司独特的表达系统代表了一种以工业规模开发重组蛋白的新方法。该公司的战略重点是开发主要通过ProCellEx生产的定制复杂重组治疗性蛋白质,同时在生产前和生产后对蛋白质进行基因工程和化学修饰。该公司打算通过改进治疗蛋白的生物学特性(例如,糖基化、半衰期、免疫原性),进行此类工程设计和修改,以提供额外的临床益处。
发行价格:
--
{"stockData":{"symbol":"PLX","market":"US","secType":"STK","nameCN":"Protalix BioTherapeutics Inc","latestPrice":2.9,"timestamp":1770238800000,"preClose":2.73,"halted":0,"volume":2581214,"hourTrading":{"tag":"盘后","latestPrice":2.88,"preClose":2.9,"latestTime":"19:47 EST","volume":6374,"amount":18487.5833,"timestamp":1770252461012,"change":-0.02,"changeRate":-0.006897,"amplitude":0.013793},"delay":0,"changeRate":0.062271062271062244,"floatShares":60755281,"shares":80421181,"eps":0.069071,"marketStatus":"已收盘","change":0.17,"latestTime":"02-04 16:00:00 EST","open":2.74,"high":2.97,"low":2.74,"amount":7399429.369458,"amplitude":0.084249,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.069071,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770282000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":829022400000,"exchange":"AMEX","adjPreClose":2.73,"preHourTrading":{"tag":"盘前","latestPrice":2.8,"preClose":2.73,"latestTime":"09:28 EST","volume":2704,"amount":7436.363688,"timestamp":1770215311607,"change":0.07,"changeRate":0.025641,"amplitude":0.034139},"postHourTrading":{"tag":"盘后","latestPrice":2.88,"preClose":2.9,"latestTime":"19:47 EST","volume":6374,"amount":18487.5833,"timestamp":1770252461012,"change":-0.02,"changeRate":-0.006897,"amplitude":0.013793},"volumeRatio":1.321748,"impliedVol":1.193,"impliedVolPercentile":0.753},"requestUrl":"/m/hq/s/PLX","defaultTab":"news","newsList":[{"id":"2608133842","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 早盘股价大涨5.00%报2.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608133842","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608133842?lang=zh_cn&edition=full","pubTime":"2026-02-03 23:00","pubTimestamp":1770130851,"startTime":"0","endTime":"0","summary":"北京时间2026年02月03日23时00分,Protalix Biotherapeutics, Inc. 股票出现异动,股价大幅上涨5.00%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中,整体涨幅为1.00%。其相关个股中,Liminatus Pharma Inc C/Wts 30/04/2030 、Jasper Therapeutics Inc C/Wts 24/09/2026 、Liminatus Pharma, Inc.涨幅较大,Cdt Equity Inc.、Pmgc Holdings Inc.、Liminatus Pharma, Inc.较为活跃,换手率分别为631.66%、578.09%、51.10%,振幅较大的相关个股有Liminatus Pharma Inc C/Wts 30/04/2030 、Briacell Therapeutics Corp C/Wts 26/02/2026、Bioatla, Inc.,振幅分别为70.33%、32.58%、24.70%。Protalix Biotherapeutics, Inc. 公司简介:Protalix BioTherapeutics Inc是一家生物制药公司,专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203230051a6cf0931&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203230051a6cf0931&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"1150104851","title":"Protalix BioTherapeutics 第三季度每股收益为0.03美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1150104851","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150104851?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:40","pubTimestamp":1763574048,"startTime":"0","endTime":"0","summary":"11月13日 - Protalix BioTherapeutics 第三季度税前利润为223.9万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"1106718567","title":"奇耶斯全球罕见疾病请求欧洲药品管理局对Elfabrio 2 mg/kg每四周给药方案的负面意见进行重新审查","url":"https://stock-news.laohu8.com/highlight/detail?id=1106718567","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106718567?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:30","pubTimestamp":1763569859,"startTime":"0","endTime":"0","summary":"11月3日——奇耶斯全球罕见疾病公司请求欧洲药品管理局(EMA)药物评审委员会(CHMP)对其提出的每四周给药2 mg/kg的Elfabrio方案的负面意见进行重新审查。奇耶斯全球罕见疾病公司和Protalix BioTherapeutics正在向EMA申请重新审查Elfabrio(Pegunigalsidase Alfa)在欧盟的替代给药方案的负面意见。目前Elfabrio的现有市场授权仍然有效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"1183889421","title":"Protalix BioTherapeutics 第三季度每股收益为0.03美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183889421","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183889421?lang=zh_cn&edition=full","pubTime":"2025-11-13 20:09","pubTimestamp":1763035744,"startTime":"0","endTime":"0","summary":"11月13日 - Protalix BioTherapeutics 第三季度税前利润为223.9万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"1189273756","title":"奇耶西全球罕见病公司申请重新审查欧洲药品管理局CHMP对Elfabrio 2 mg/kg每4周给药方案的负面意见","url":"https://stock-news.laohu8.com/highlight/detail?id=1189273756","media":"投资观察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189273756?lang=zh_cn&edition=full","pubTime":"2025-11-04 07:47","pubTimestamp":1762213677,"startTime":"0","endTime":"0","summary":"11月3日(路透社) - 奇耶西全球罕见病公司请求重新审查欧洲药品管理局(EMA)药品人用委员会(CHMP)对Elfabrio(PEGUNIGALSIDASE ALFA)每4周2 mg/kg给药方案的负面意见,同时与Protalix BioTherapeutics共同寻求对此持否定态度的重新审查。现有的Elfabrio市场授权依然生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2573983236","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 下午盘股价大涨5.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2573983236","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2573983236?lang=zh_cn&edition=full","pubTime":"2025-10-07 02:09","pubTimestamp":1759774187,"startTime":"0","endTime":"0","summary":"北京时间2025年10月07日02时09分,Protalix Biotherapeutics, Inc. 股票出现波动,股价快速拉升5.35%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中,整体涨幅为0.43%。其相关个股中,Leap Therapeutics, Inc.、Sab Biotherapeutics Inc C/Wts 22/10/2026 、Kalaris Therapeutics, Inc.涨幅较大,Palisade Bio, Inc.、Leap Therapeutics, Inc.、Cdt Equity Inc.较为活跃,换手率分别为474.88%、216.68%、143.27%,振幅较大的相关个股有Leap Therapeutics, Inc.、Sab Biotherapeutics Inc C/Wts 22/10/2026 、Moolec Science Sa C/Wts ,振幅分别为61.63%、56.38%、50.94%。Protalix Biotherapeutics, Inc. 公司简介:Protalix BioTherapeutics Inc是一家生物制药公司,专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251007020947a6af0b7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251007020947a6af0b7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2570080102","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 临近收盘急速拉升5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2570080102","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570080102?lang=zh_cn&edition=full","pubTime":"2025-09-25 03:39","pubTimestamp":1758742759,"startTime":"0","endTime":"0","summary":"北京时间2025年09月25日03时39分,Protalix Biotherapeutics, Inc. 股票出现波动,股价大幅拉升5.10%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中,整体涨幅为0.22%。其相关个股中,Uniqure N.V.、Tnf Pharmaceuticals, Inc.、Akari Therapeutics Plc涨幅较大,Tnf Pharmaceuticals, Inc.、Cyclerion Therapeutics, Inc.、Uniqure N.V.较为活跃,换手率分别为3194.88%、442.20%、121.12%,振幅较大的相关个股有Tnf Pharmaceuticals, Inc.、Uniqure N.V.、Akari Therapeutics Plc,振幅分别为135.04%、103.15%、60.49%。Protalix Biotherapeutics, Inc. 公司简介:Protalix BioTherapeutics Inc是一家生物制药公司,专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925033919a69be85e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925033919a69be85e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2566612950","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 快速拉升5.06%报1.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2566612950","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566612950?lang=zh_cn&edition=full","pubTime":"2025-09-10 00:33","pubTimestamp":1757435599,"startTime":"0","endTime":"0","summary":"北京时间2025年09月10日00时33分,Protalix Biotherapeutics, Inc. 股票出现波动,股价急速上涨5.06%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中,整体涨幅为0.51%。Protalix Biotherapeutics, Inc. 公司简介:Protalix BioTherapeutics Inc是一家生物制药公司,专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250910003320a4beddbe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250910003320a4beddbe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2558646106","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 急速拉升5.19%报1.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558646106","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558646106?lang=zh_cn&edition=full","pubTime":"2025-08-12 00:07","pubTimestamp":1754928478,"startTime":"0","endTime":"0","summary":"北京时间2025年08月12日00时07分,Protalix Biotherapeutics, Inc. 股票出现波动,股价大幅拉升5.19%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中,整体涨幅为0.38%。其相关个股中,Equillium, Inc.、Entero Therapeutics Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 涨幅较大,Entero Therapeutics Inc.、Equillium, Inc.、Bioxcel Therapeutics, Inc.较为活跃,换手率分别为5804.94%、551.05%、187.28%,振幅较大的相关个股有Equillium, Inc.、Entero Therapeutics Inc.、Jyong Biotech Ltd.,振幅分别为84.05%、74.27%、62.69%。Protalix Biotherapeutics, Inc. 公司简介:Protalix BioTherapeutics Inc是一家生物制药公司,专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081200075897411f13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081200075897411f13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2514373584","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 早盘大幅下跌5.15%报2.21美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514373584","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514373584?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:35","pubTimestamp":1740753342,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时35分,Protalix Biotherapeutics, Inc. 股票出现波动,股价快速下跌5.15%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中,整体涨幅为0.16%。其相关个股中,Enveric Biosciences, Inc.、Tc Biopharm Plc C/Wts 10/02/2028 、Virpax Pharmaceuticals, Inc.涨幅较大,Bioxcel Therapeutics, Inc.、Virpax Pharmaceuticals, Inc.、Enveric Biosciences, Inc.较为活跃,换手率分别为492.73%、249.70%、156.36%,振幅较大的相关个股有Cardio Diagnostics Holdings Inc C/Wts To Pur Com、Enveric Biosciences, Inc.、Anaptysbio, Inc.,振幅分别为31.14%、27.83%、16.10%。Protalix Biotherapeutics, Inc. 公司简介:Protalix BioTherapeutics Inc是一家生物制药公司,专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822354298967ae3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822354298967ae3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2512616126","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 早盘股价大跌5.02%报2.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512616126","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512616126?lang=zh_cn&edition=full","pubTime":"2025-02-18 23:28","pubTimestamp":1739892514,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时28分,Protalix Biotherapeutics, Inc. 股票出现异动,股价快速下跌5.02%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中,整体涨幅为0.66%。其相关个股中,Estrella Immunopharma Inc C/Wts 29/09/2028、Allogene Therapeutics, Inc.、Solid Biosciences Inc.涨幅较大,Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃,换手率分别为363.37%、156.72%、137.36%,振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Allogene Therapeutics, Inc.、Lixte Biotechnology Holdings Inc C/Wts 30/11/2025 ,振幅分别为148.75%、79.17%、51.40%。Protalix Biotherapeutics, Inc. 公司简介:Protalix BioTherapeutics Inc是一家生物制药公司,专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182328349627a26a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182328349627a26a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2509258027","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 快速拉升5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509258027","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509258027?lang=zh_cn&edition=full","pubTime":"2025-02-06 03:32","pubTimestamp":1738783942,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日03时32分,Protalix Biotherapeutics, Inc. 股票出现异动,股价急速上涨5.16%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中,整体涨幅为2.41%。其相关个股中,Invivyd, Inc.、Transcode Therapeutics, Inc.、Pasithea Therapeutics Corp.涨幅较大,Pasithea Therapeutics Corp.、Transcode Therapeutics, Inc.、Oragenics Inc.较为活跃,换手率分别为4639.31%、2353.35%、1754.71%,振幅较大的相关个股有Oragenics Inc.、Transcode Therapeutics, Inc.、Invivyd, Inc.,振幅分别为132.24%、99.51%、69.59%。Protalix Biotherapeutics, Inc. 公司简介:Protalix BioTherapeutics Inc是一家生物制药公司,专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206033222abc3bc29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206033222abc3bc29&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2507250375","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 急速上涨5.38%报2.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507250375","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507250375?lang=zh_cn&edition=full","pubTime":"2025-01-29 04:42","pubTimestamp":1738096929,"startTime":"0","endTime":"0","summary":"北京时间2025年01月29日04时42分,Protalix Biotherapeutics, Inc. 股票出现波动,股价快速上涨5.38%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中,整体涨幅为0.12%。Protalix Biotherapeutics, Inc. 公司简介:Protalix BioTherapeutics Inc是一家生物制药公司,专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012904421096131c10&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012904421096131c10&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2506588593","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 急速下跌5.28%报2.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506588593","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506588593?lang=zh_cn&edition=full","pubTime":"2025-01-28 01:29","pubTimestamp":1737998941,"startTime":"0","endTime":"0","summary":"北京时间2025年01月28日01时29分,Protalix Biotherapeutics, Inc. 股票出现波动,股价急速下跌5.28%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中,整体涨幅为1.06%。其相关个股中,Akero Therapeutics, Inc.、Dogwood Therapeutics, Inc.、89Bio, Inc.涨幅较大,Onconetix, Inc.、Dogwood Therapeutics, Inc.、Allarity Therapeutics, Inc.较为活跃,换手率分别为2103.25%、858.03%、248.62%,振幅较大的相关个股有Dogwood Therapeutics, Inc.、Onconetix, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028,振幅分别为108.60%、85.35%、65.16%。Protalix Biotherapeutics, Inc. 公司简介:Protalix BioTherapeutics Inc是一家生物制药公司,专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250128012901abba8474&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250128012901abba8474&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2505029988","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 临近收盘股价大涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505029988","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505029988?lang=zh_cn&edition=full","pubTime":"2025-01-24 04:42","pubTimestamp":1737664973,"startTime":"0","endTime":"0","summary":"北京时间2025年01月24日04时42分,Protalix Biotherapeutics, Inc. 股票出现异动,股价大幅拉升5.06%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中,整体涨幅为1.86%。其相关个股中,Dogwood Therapeutics, Inc.、Nutriband Inc C/Wts 、Transcode Therapeutics, Inc.涨幅较大,Hepion Pharmaceuticals, Inc.、Dogwood Therapeutics, Inc.、Transcode Therapeutics, Inc.较为活跃,换手率分别为7526.36%、7515.98%、1290.26%,振幅较大的相关个股有Dogwood Therapeutics, Inc.、Transcode Therapeutics, Inc.、Nutriband Inc C/Wts ,振幅分别为948.57%、261.32%、172.73%。Protalix Biotherapeutics, Inc. 公司简介:Protalix BioTherapeutics Inc是一家生物制药公司,专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124044253960e878a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124044253960e878a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2505204100","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 股价大涨5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505204100","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505204100?lang=zh_cn&edition=full","pubTime":"2025-01-22 01:35","pubTimestamp":1737480925,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日01时35分,Protalix Biotherapeutics, Inc. 股票出现波动,股价急速上涨5.41%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中,整体涨幅为2.01%。其相关个股中,Dogwood Therapeutics, Inc.、Camp4 Therapeutics Corporation、Cardio Diagnostics Holdings Inc C/Wts To Pur Com涨幅较大,Dogwood Therapeutics, Inc.、Channel Therapeutics Corporation、Dermata Therapeutics, Inc.较为活跃,换手率分别为791.45%、506.92%、187.49%,振幅较大的相关个股有Channel Therapeutics Corporation、Klotho Neurosciences Inc C/Wts 21/06/2029 、Dogwood Therapeutics, Inc.,振幅分别为96.32%、41.33%、38.48%。Protalix Biotherapeutics, Inc. 公司简介:Protalix BioTherapeutics Inc是一家生物制药公司,专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122013525abb36e43&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122013525abb36e43&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2503828105","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 早盘急速下挫5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503828105","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503828105?lang=zh_cn&edition=full","pubTime":"2025-01-14 00:04","pubTimestamp":1736784272,"startTime":"0","endTime":"0","summary":"北京时间2025年01月14日00时04分,Protalix Biotherapeutics, Inc. 股票出现异动,股价大幅下挫5.29%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中,整体跌幅为1.04%。其相关个股中,Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Kairos Pharma, Ltd.涨幅较大,Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Silexion Therapeutics Corp较为活跃,换手率分别为11054.97%、5944.38%、422.33%,振幅较大的相关个股有Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Kairos Pharma, Ltd.,振幅分别为336.09%、216.61%、124.54%。Protalix Biotherapeutics, Inc. 公司简介:Protalix BioTherapeutics Inc是一家生物制药公司,专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501140004329864e697&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501140004329864e697&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2501560332","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 早盘股价大涨5.18%报2.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501560332","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501560332?lang=zh_cn&edition=full","pubTime":"2025-01-06 22:35","pubTimestamp":1736174120,"startTime":"0","endTime":"0","summary":"北京时间2025年01月06日22时35分,Protalix Biotherapeutics, Inc. 股票出现异动,股价快速拉升5.18%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中,整体跌幅为0.17%。其相关个股中,Scisparc Ltd.、Sab Biotherapeutics Inc C/Wts 22/10/2026 、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 涨幅较大,Scisparc Ltd.、Cns Pharmaceuticals, Inc.、Aditxt, Inc.较为活跃,换手率分别为438.24%、219.87%、54.55%,振幅较大的相关个股有Scisparc Ltd.、Renovaro Inc.、Cns Pharmaceuticals, Inc.,振幅分别为32.18%、21.60%、15.20%。Protalix Biotherapeutics, Inc. 公司简介:Protalix BioTherapeutics Inc是一家生物制药公司,专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010622352095fa7361&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010622352095fa7361&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2500909178","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 股价大涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2500909178","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500909178?lang=zh_cn&edition=full","pubTime":"2025-01-03 04:17","pubTimestamp":1735849059,"startTime":"0","endTime":"0","summary":"北京时间2025年01月03日04时17分,Protalix Biotherapeutics, Inc. 股票出现异动,股价快速上涨5.26%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中,整体涨幅为0.46%。Protalix Biotherapeutics, Inc. 公司简介:Protalix BioTherapeutics Inc是一家生物制药公司,专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103041739985940f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103041739985940f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2495528755","title":"Protalix Biotherapeutics, Inc. (De)盘中异动 早盘股价大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2495528755","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495528755?lang=zh_cn&edition=full","pubTime":"2024-12-30 22:31","pubTimestamp":1735569088,"startTime":"0","endTime":"0","summary":"北京时间2024年12月30日22时31分,Protalix Biotherapeutics, Inc. 股票出现异动,股价大幅拉升5.03%。Protalix Biotherapeutics, Inc. 股票所在的生物技术行业中,整体跌幅为0.43%。其相关个股中,Polyrizon Ltd.、Vincerx Pharma, Inc.、Nls Pharmaceutics Ltd.涨幅较大,Nls Pharmaceutics Ltd.、Polyrizon Ltd.、Vincerx Pharma, Inc.较为活跃,换手率分别为679.16%、318.45%、79.71%,振幅较大的相关个股有Marinus Pharmaceuticals, Inc.、Quoin Pharmaceuticals Ltd、Aditxt, Inc.,振幅分别为142.70%、116.36%、110.43%。Protalix Biotherapeutics, Inc. 公司简介:Protalix BioTherapeutics Inc是一家生物制药公司,专注于基于其专有的ProCellEx蛋白表达系统的重组治疗蛋白的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241230223128985524ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241230223128985524ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PLX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.protalix.com","stockEarnings":[{"period":"1week","weight":0.2877},{"period":"1month","weight":0.569},{"period":"3month","weight":0.1471},{"period":"6month","weight":0.8079},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.5167}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":0.0093},{"period":"3month","weight":0.0176},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.1535},{"period":"ytd","weight":0.0112}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Protalix Biotherapeutics, Inc.最初于1992年4月在佛罗里达州注册成立,并于2016年3月在特拉华州重新注册成立。该公司是一家生物制药公司,专注于开发、生产和商业化由专有的ProCellEx植物细胞蛋白表达系统生产的重组治疗蛋白。该公司是第一家也是唯一一家获得FDA批准的通过植物细胞表达悬浮蛋白生产的公司。该公司独特的表达系统代表了一种以工业规模开发重组蛋白的新方法。该公司的战略重点是开发主要通过ProCellEx生产的定制复杂重组治疗性蛋白质,同时在生产前和生产后对蛋白质进行基因工程和化学修饰。该公司打算通过改进治疗蛋白的生物学特性(例如,糖基化、半衰期、免疫原性),进行此类工程设计和修改,以提供额外的临床益处。","yearOnYearQuotes":[{"month":1,"riseRate":0.736842,"avgChangeRate":0.12158},{"month":2,"riseRate":0.421053,"avgChangeRate":0.050779},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.033546},{"month":4,"riseRate":0.578947,"avgChangeRate":0.056427},{"month":5,"riseRate":0.210526,"avgChangeRate":-0.051275},{"month":6,"riseRate":0.421053,"avgChangeRate":-0.034716},{"month":7,"riseRate":0.368421,"avgChangeRate":-0.04582},{"month":8,"riseRate":0.368421,"avgChangeRate":-0.012213},{"month":9,"riseRate":0.421053,"avgChangeRate":0.05112},{"month":10,"riseRate":0.421053,"avgChangeRate":-0.052252},{"month":11,"riseRate":0.368421,"avgChangeRate":-0.008211},{"month":12,"riseRate":0.421053,"avgChangeRate":-0.008649}],"exchange":"AMEX","name":"Protalix BioTherapeutics Inc","nameEN":"Protalix BioTherapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Protalix BioTherapeutics Inc(PLX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Protalix BioTherapeutics Inc(PLX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Protalix BioTherapeutics Inc,PLX,Protalix BioTherapeutics Inc股票,Protalix BioTherapeutics Inc股票老虎,Protalix BioTherapeutics Inc股票老虎国际,Protalix BioTherapeutics Inc行情,Protalix BioTherapeutics Inc股票行情,Protalix BioTherapeutics Inc股价,Protalix BioTherapeutics Inc股市,Protalix BioTherapeutics Inc股票价格,Protalix BioTherapeutics Inc股票交易,Protalix BioTherapeutics Inc股票购买,Protalix BioTherapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Protalix BioTherapeutics Inc(PLX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Protalix BioTherapeutics Inc(PLX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}